KR970704889A - 핵산-함유 조성물, 이의 제조 방법 및 용도 - Google Patents

핵산-함유 조성물, 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR970704889A
KR970704889A KR1019970700200A KR19970700200A KR970704889A KR 970704889 A KR970704889 A KR 970704889A KR 1019970700200 A KR1019970700200 A KR 1019970700200A KR 19970700200 A KR19970700200 A KR 19970700200A KR 970704889 A KR970704889 A KR 970704889A
Authority
KR
South Korea
Prior art keywords
composition
nucleic acid
polymer
composition according
formula
Prior art date
Application number
KR1019970700200A
Other languages
English (en)
Other versions
KR100424802B1 (ko
Inventor
장-폴 베르
오뜨망 부시프
바바라 데멘익스
프락 레주알츠
모간 머그니
다니엘 쉐르망
Original Assignee
필립프 베커
롱프랑 로라 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970704889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 필립프 베커, 롱프랑 로라 소시에테 아노님 filed Critical 필립프 베커
Publication of KR970704889A publication Critical patent/KR970704889A/ko
Application granted granted Critical
Publication of KR100424802B1 publication Critical patent/KR100424802B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

하나 이상의 핵산 및 양이온 중합체를 함유하는 조성물, 및 특히 생체내 헥산 전달을 위한 유전자 치료에서의 이의 용도.

Description

핵산-함유 조성물, 이의 제조 방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
도 1: (중합체 아민/핵산 포스페이트) 비 R로 나타낸 pH7에서 PEI800K의 형질감염 효율.
도 2: DNA의 양으로 나타낸 pH6에서 PEI800K의 형질감염 효율.
도 3: 비 R로 나타낸 pH6에서 PEI800K의 형질감염 효율.
도 5: PEI800K와 폴리리신간의 비교.
도 7: 보조제의 존채하에 PEI50K의 형질감염 효율.

Claims (30)

  1. 적어도 하나의 핵산 및 화학식(I)의 양이온 중합체를 포함하는 조성물:
    [화학식 I]
    상기식에서,
    R은 수소 원자 또는 화학식의 그룹일 수 있고, n은 2 내지 10의 정수이며 p 및 q는 정수이며,
    p와 q의 합은 중합체의 평균 분자량이 100 내지 107이 되게 하는 값이다.
  2. 제 1 항에 있어서, 화학식 (I)에서 n이 2 내지 5인 것을 특징으로 하는 조성물.
  3. 제 1 또는 2 항에 있어서, 중합체가 103 내지 5×106의 평균 분자량을 갖는 것을 특징으로 하는 조성물.
  4. 제 1 내지 3 항중 어느 한 항에 있어서, 중합체가 폴리에틸렌이민(PEI) 및 폴리프로필렌이민(PPI)으로부터 선택되는 것을 특징으로 하는 조성물.
  5. 제 4 항에 있어서, 중합체가 평균 분자량 50,000의 폴리에틸렌이민(PEI50K) 및 평균 분자량 800,000의 폴리에틸렌이민(PEI800K)으로부터 선택되는 것을 특징으로 하는 조성물.
  6. 제 1 내지 5 항중 어느 한 항에 있어서, 중합체 및 핵산의 각각의 부분이 중합체 아민/핵산 포스페이트비 R이 0.5 내지 50 사이인 방식으로 선택되는 것을 특징으로 하는 조성물.
  7. 제 6 항에 있어서, 비 R이 2 내지 50인 것을 특징으로 하는 조성물.
  8. 제 7 항에 있어서, 비 R이 5 내지 30인 것을 특징으로 하는 조성물.
  9. 제 1 내지 8 항중 어느 한 항에 있어서, 중합체/핵산 복합물과 배합될 수 있고 형질감염력을 개선시킬수 있는 하나 이상의 보조제를 추가로 포함하는 것을 특징으로 하는 조성물.
  10. 제 9 항에 있어서, 보조제가 지질, 단백질, 리포폴리아민 및 합성 중합체로부터 선택되는 것을 특징으로하는 조성물.
  11. 제 10 항에 있어서, 보조제가 양이온 지질인 것을 특징으로 하는 조성물.
  12. 제 11 항에 있어서, 양이온 지질이 하나 이상의 리포폴리아민인 것을 특징으로 하는 조성물.
  13. 제 12 항에 있어서, 리포폴리아민이 m이 2 이상의 정수로서 두개의 아민사이에 놓인 상이한 탄소 그룹간에 변화가능하고, l이 1 이상의 정수인 화학식 H2N-(-(CH)m-NH-)l-H에 상응하는 것을 특징으로 하는 조성물.
  14. 제 13 항에 있어서, 리포폴리아민이 디옥타데실아미도글리실스퍼민(DOGS) 또는 팔미토일포스파티딜에탄올아민 5-카복시스퍼밀아미드(DPPES)로부터 선택되는 것을 특징으로 하는 조성물.
  15. 제 10 항에 있어서, 보조제가 하나 이상의 중성 지질인 것을 특징으로 하는 조성물.
  16. 제 15 항에 있어서, 중성 지질(들)이 양쪽성이거나 생리학적 조건하에 이온 전하가 부족한 합성 또는 천연 지질중에서 선택되는 것을 특징으로 하는 조성물.
  17. 제 16 항에 있어서, 중성 지질(들)이 2개의 지방 사슬을 포함하는 지질인 것을 특징으로 하는 조성물.
  18. 제 16 항에 있어서, 중성 지질(들)이 디올레오일포스파티딜에탄올아민(DOPE), 올레오일팔미토일포스파티딜에탄올아민(POPE), 디스테아로일-, 팔미토일- 및 미리스토일포스파티딜에탄올아민 및 이들의 1- 내지 3-중 N-메틸화된 유도체; 포스파티딜글리세롤, 디아실글리세롤, 글리코실디아실글리세롤, 세레브로시드(예를 들면, 특히 갈락토세레브로시드), 스핑고리피드(예를 들면, 특히 스핑고미엘린) 또는 아시알로강글리오시드(예를 들면, 특히 아시알로GM1 및 -GM2)로부터 선택되는 것을 특징으로 하는 조성물.
  19. 제 1 항에 있어서, 핵산이 DNA인 것을 특징으로 하는 조성물.
  20. 제 1 항에 있어서, 핵산이 RNA인 것을 특징으로 하는 조성물.
  21. 제 19 또는 20 항에 있어서, 핵산이 화학적으로 변형되는 것을 특징으로 하는 조성물.
  22. 제 19 내지 21 항중 어느 한 항에 있어서, 핵산이 안티센스 서열인 것을 특징으로 하는 조성물.
  23. 제 19 내지 22 항중 어느 한 항에 있어서, 핵산이 치료 유전자를 함유하는 것을 특징으로 하는 조성물.
  24. 제 9 항에 있어서, 핵산 포스페이트의 몰당량 당 O.1 내지 20 몰당량, 보다 바람직하게는 1 내지 5 몰당량의 보조제를 포함하는 것을 특징으로 하는 조성물.
  25. 제 1 내지 24 항중 어느 한 항에 있어서, 표적화 요소를 포함하는 것을 특징으로 하는 조성물.
  26. 제 25 항에 있어서, 표적화 요소가 당 및/또는 항체 또는 항체 단편, 세포 수용체 리간드 또는 이의 단편, 또는 수용체 또는 수용체 단편같은 펩티드로 이루어지는 것을 특징으로 하는 조성물.
  27. 제 25 또는 26 항에 있어서, 표적화 요소가 화학식 (I)의 중합체와 공유 결합하는 것을 특징으로 하는 조성물.
  28. 제 1 내지 27 항중 어느 한 항에 있어서, 주사제용으로 약학적으로 허용되는 담체를 포함하는 것을 특징으로 하는 조성물.
  29. 제 1 내지 28 항중 어느 한 항에 있어서, 피부 및/또는 점막에 적용하가 위해 약학적으로 허용되는 담체를 포함하는 것을 특징으로 하는 조성물.
  30. 핵산을 세포내로 전달하기 위한 제 1 항에 따른 양이온 중합체의 용도.
KR1019970700200A 1994-07-13 1995-07-07 핵산-함유조성물,이의제조방법및용도 KR100424802B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94/08735 1994-07-13
FR9408735A FR2722506B1 (fr) 1994-07-13 1994-07-13 Composition contenant des acides nucleiques, preparation et utilisations

Publications (2)

Publication Number Publication Date
KR970704889A true KR970704889A (ko) 1997-09-06
KR100424802B1 KR100424802B1 (ko) 2004-06-23

Family

ID=9465376

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700200A KR100424802B1 (ko) 1994-07-13 1995-07-07 핵산-함유조성물,이의제조방법및용도

Country Status (18)

Country Link
US (1) US6013240A (ko)
EP (1) EP0770140B1 (ko)
JP (1) JP4275728B2 (ko)
KR (1) KR100424802B1 (ko)
AT (1) ATE367448T1 (ko)
AU (1) AU2930795A (ko)
CA (1) CA2194797C (ko)
DE (1) DE69535540T9 (ko)
DK (1) DK0770140T3 (ko)
ES (1) ES2290952T3 (ko)
FI (1) FI119738B (ko)
FR (1) FR2722506B1 (ko)
IL (1) IL114566A (ko)
MX (1) MX9700270A (ko)
NO (1) NO323110B1 (ko)
PT (1) PT770140E (ko)
WO (1) WO1996002655A1 (ko)
ZA (1) ZA955849B (ko)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL122290A0 (en) * 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
EP0934082B1 (de) * 1996-10-23 2002-07-17 SKW Trostberg Aktiengesellschaft Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
US6071533A (en) 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
KR100615117B1 (ko) 1997-09-15 2006-08-22 제네틱 이뮤너티, 엘엘씨. 피부의 항원제시 세포에 유전자를 전달하는 방법
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
DE19743135A1 (de) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
WO1999065531A1 (en) * 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
EP1044679B1 (en) * 1998-11-02 2012-12-26 Terumo Kabushiki Kaisha Stable Liposomes for Targeted Drug Delivery
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
ATE338540T1 (de) * 1999-04-02 2006-09-15 Res Dev Foundation Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
EP1156832A1 (en) 1999-12-28 2001-11-28 Transgene S.A. Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
JP2003519199A (ja) * 1999-12-30 2003-06-17 ノバルティス アクチエンゲゼルシャフト 遺伝子治療のための新規なコロイド合成ベクター
FR2805271B1 (fr) * 2000-02-18 2002-04-26 Aventis Pharma Sa Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
HUP0303379A3 (en) * 2000-09-05 2004-03-01 Gencell Sa Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them
FR2813605B1 (fr) * 2000-09-05 2002-10-18 Aventis Pharma Sa Composes acidosensibles, leur preparation et utilisations
FR2814370B1 (fr) 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
DE10145134A1 (de) * 2000-10-09 2002-05-16 Bayer Ag Komplexe zur Einführung von Nukleinsäuren in Zellen
AU2001289943A1 (en) * 2000-10-09 2002-04-22 Bayer Aktiengesellschaft Complexes for transferring nucleic acids into cells
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
CA2437555A1 (en) * 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040234586A1 (en) * 2001-06-11 2004-11-25 Sylvain Meloche Compositions and methods for enhancing nucleic acid transfer into cells
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP2005508396A (ja) * 2001-11-02 2005-03-31 イントラディグム、コーポレイション 核酸送達ビヒクルのための治療方法
HUE036402T2 (hu) 2002-01-17 2018-07-30 Alfa Laval Corp Ab Merülõpárologtató, amely lemezes hõcserélõt és hengeres házat tartalmaz, ahol a lemezes hõcserélõ el van helyezve
WO2003089618A2 (en) * 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
WO2003099225A2 (en) 2002-05-24 2003-12-04 Mirus Corporation Compositions for delivering nucleic acids to cells
ATE485031T1 (de) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
CA2498777C (en) * 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
EP2567693B1 (en) 2003-07-16 2015-10-21 Protiva Biotherapeutics Inc. Lipid encapsulated interfering RNA
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
EP1737956A2 (en) * 2004-03-01 2007-01-03 Massachusetts Institute of Technology Rnai-based therapeutics for allergic rhinitis and asthma
WO2005089123A2 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer dna
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7807815B2 (en) 2004-07-02 2010-10-05 Protiva Biotherapeutics, Inc. Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
EP2047858A1 (en) 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
WO2009065618A2 (de) 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
US7687027B2 (en) * 2008-02-27 2010-03-30 Becton, Dickinson And Company Cleaning compositions, methods and materials for reducing nucleic acid contamination
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
JP2011516094A (ja) 2008-04-15 2011-05-26 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2285969B1 (en) * 2008-05-15 2013-01-16 National Research Council Of Canada Use of protein kinase b and valproic acid to increase heterologous gene expression in mammalian cells
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
WO2010078194A1 (en) * 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE102009006606A1 (de) 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
NO2398912T3 (ko) 2009-02-18 2018-02-10
WO2010125544A1 (en) 2009-04-30 2010-11-04 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
WO2011057184A1 (en) 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
ES2640906T3 (es) 2010-03-24 2017-11-07 Institut National De La Sante Et De La Recherche Medicale Modelo primate de la familia de los cercopitécidos infectado por una cepa del VHB de genotipo humano
WO2011120953A1 (en) 2010-03-29 2011-10-06 Universite De Strasbourg Polymers for delivering molecules of interest
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
SI3135301T1 (en) 2010-06-22 2018-08-31 Onxeo OPTIMIZED SYSTEM OF DELIVERY AND VIVO WITH ENDOSOMOLITIC MEANS FOR KONJUGATE NUCLEIC ACIDS
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
CA2856455C (en) 2011-11-24 2022-08-23 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
ES2826203T3 (es) * 2012-06-08 2021-05-17 Ethris Gmbh Suministro pulmonar de ARN mensajero
CN103059295B (zh) * 2012-09-26 2016-01-13 上海交通大学 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途
DK2903652T3 (da) 2012-10-05 2022-07-04 Biontech Delivery Tech Gmbh Hydroxylerede polyaminderivater som transfektionsreagenser
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
DE102012111891A1 (de) * 2012-12-06 2014-06-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbesserung der Zielfindungskapazität von Stammzellen
CA2917912C (en) 2013-07-24 2019-09-17 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US20160296632A1 (en) 2013-11-13 2016-10-13 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
KR20170075742A (ko) 2014-10-02 2017-07-03 프로티바 바이오쎄라퓨틱스, 인코포레이티드 B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
BR112017023788A2 (pt) 2015-05-05 2018-10-16 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10010627B2 (en) 2016-06-03 2018-07-03 International Business Machines Corporation Modified polycationic polymers
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
EP3541420A2 (en) 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3570814B1 (en) 2017-01-19 2023-11-29 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
KR102637960B1 (ko) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물
EP3618854A1 (en) 2017-05-02 2020-03-11 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
US20210261647A1 (en) 2018-05-15 2021-08-26 Immunomic Therapeutics, Inc Lamp constructs comprising allergens
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
CN112237633B (zh) * 2020-10-22 2023-06-27 林君玉 一种pei/on复合物及其制备方法和用途
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
IL308705A (en) 2021-06-08 2024-01-01 Touchlight Ip Ltd LENTIVIRAL vector
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993020090A1 (en) * 1992-04-06 1993-10-14 University Of Medicine & Dentistry Of New Jersey Paired-ion oligonucleotides and methods for preparing same
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Also Published As

Publication number Publication date
NO970049D0 (no) 1997-01-07
US6013240A (en) 2000-01-11
JP4275728B2 (ja) 2009-06-10
DE69535540T2 (de) 2008-06-19
CA2194797C (fr) 2010-03-23
FI119738B (fi) 2009-02-27
IL114566A (en) 2005-08-31
EP0770140B1 (fr) 2007-07-18
WO1996002655A1 (fr) 1996-02-01
JPH10502918A (ja) 1998-03-17
ZA955849B (en) 1996-02-21
NO323110B1 (no) 2007-01-02
FI970115A (fi) 1997-01-10
DK0770140T3 (da) 2007-11-19
IL114566A0 (en) 1995-11-27
ATE367448T1 (de) 2007-08-15
DE69535540D1 (de) 2007-08-30
FI970115A0 (fi) 1997-01-10
KR100424802B1 (ko) 2004-06-23
FR2722506A1 (fr) 1996-01-19
ES2290952T3 (es) 2008-02-16
MX9700270A (es) 1997-05-31
EP0770140A1 (fr) 1997-05-02
DE69535540T9 (de) 2012-03-15
FR2722506B1 (fr) 1996-08-14
NO970049L (no) 1997-01-07
AU2930795A (en) 1996-02-16
CA2194797A1 (fr) 1996-02-01
PT770140E (pt) 2007-10-19

Similar Documents

Publication Publication Date Title
KR970704889A (ko) 핵산-함유 조성물, 이의 제조 방법 및 용도
US6287591B1 (en) Charged therapeutic agents encapsulated in lipid particles containing four lipid components
EP1019365B1 (en) Novel compositions for the delivery of negatively charged molecules
KR101366482B1 (ko) 코팅된 지질 복합체 및 이들의 용도
US7807815B2 (en) Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
CA2270396C (en) Cationic reagents for transfection
US20100004315A1 (en) Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
EP1320386B1 (en) A novel cationic lipopolymer as biocompatible gene delivery agent
CA2163364C (en) Self-assembling polynucleotide delivery system comprising dendrimer polycations
US20100178699A1 (en) Multi-chain lipophilic polyamines
CA2237316A1 (en) Complex cationic lipids
EP2206787A3 (en) Peptide-enhanced transfections
JPH11512712A (ja) 生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物
CN101903018A (zh) 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
CN114507195A (zh) 一种脂质化合物、包含其的组合物及应用
CN117017939A (zh) 脂质纳米颗粒及包含其的药物组合物
US20230149562A1 (en) Carriers for efficient nucleic acid delivery
JP2024512770A (ja) 遺伝子送達における非ウイルスベクターとしての樹状構造
US7368129B1 (en) Amphiphilic materials and liposome formulations thereof
JP2012060997A (ja) 遺伝子導入用組成物およびその利用

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130221

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20140220

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20150226

Year of fee payment: 12

EXPY Expiration of term